Rituximab

Drugs of Today

Volumn 41, Issue 12, 2005, Pages 785-797

  Doan, Tanya ^a   Massarotti, Elena ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; AZATHIOPRINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXORUBICIN; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINCRISTINE;

APPENDICITIS; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; BACTERIAL ARTHRITIS; BRONCHOSPASM; CHILL; CLINICAL TRIAL; CRYOGLOBULINEMIA; DERMATOMYOSITIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GOODPASTURE SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MYASTHENIA GRAVIS; NAUSEA; NONHODGKIN LYMPHOMA; PATHOGENESIS; PEMPHIGUS; PNEUMONIA; PURE RED CELL ANEMIA; RASH; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; SJOEGREN SYNDROME; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; URINARY TRACT INFECTION; WALDENSTROEM MACROGLOBULINEMIA; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CLINICAL TRIALS; HUMANS; LYMPHOMA, B-CELL;

EID: 33644687397     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.12.953591     Document Type: Review

References (100)

1. Anderson, K., Bates, M., Slaughenhoupt, B., Pinkus, G., Schlossman, S., Nadler, L. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 1984, 63: 1424-33.
2. Einfeld, D., Brown, J., Valentine, M., Clark, E., Ledbetter, J. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988, 7: 711-7.
3. Valentine, M., Meier, K., Rossie, S., Clark, E. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. J Biol Chem 1989, 264: 11282-7.
4. Tedder, T., Boyd, A., Freedman, A., Nadler, L., Schlossman, S. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985, 135: 973-9.
5. Tedder, T., Zhou, L., Bell, P., Frizzell, R., Bubien, J. The CD20 surface molecule of B lymphocytes functions as a calcium channel. Biochem 1990, 14D: 195.
6. Anolik, J., Luoney, R.J., Bottaro, A., Sanz, I., Young, F. Down-regulation of CD20 on B cells upon CD40 activation. Eur J Immunol 2004, 33: 2398-409.
7. Press, O., Applebaum, F., Ledbetter, J. et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 1987, 69: 584-91.
8. McLaughlin, P. Rituximab: Perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hemtol 2000, 40: 3-16.
9. Reff, M., Carner, C., Chambers, K. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83: 435-45.
10. Manches, O., Lui, G., Chaperot, L. et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101: 949-54.
11. Shan, D., Ledbetter, J., Press, O. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 91: 1644-52.
12. Tsokos, G. B cells, be gone - B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med 2004, 350: 2546-8.
13. McLaughlin, P., Grillo-Lopez, A., Link, B. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16: 2825-33.
14. Byrd, J., Murphy, T., Howard, R. et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and aceptable toxicity. J Clin Oncol 2001, 19: 2153-64.
15. Davis, T., Grillo-Lopez, A., White, C. et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 2000, 18: 3135-43.
16. Maloney, D., Grillo-Lopez, A., Bodkin, D. et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15: 3266-74.
17. Mohrbacher, A. B cell non-Hodgkin's lymphoma: Rituximab safety experience. Arthritis Res Ther 2005, 7: S19-S25.
18. Foran, J., Rohatiner, A., Cunningham, D. et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18: 317-24.
19. Cohen, Y., Solal-Celigny, P., Polliack, A. Rituximab therapy for follicular lymphoma: A comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, retreatment and maintenance. Haematologica 2003, 88: 811-23.
20. Coiffier, B., Lepage, E., Briere, J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002, 346: 235-42.
21. Czuczman, M. Combination chemotheraphy and rituximab. Anticancer Drugs 2001, 12: S15-9.
22. Hainsworth, J., Burris, H.R., Morrissey, L. et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000, 95: 3052-6.
23. Colombat, P., Salles, G., Brousse, N. et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 2001, 97: 101-6.
24. Pettengell, R., Linch, D. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 2003, 121: 44-8.
25. Coiffier, B., Haioun, C., Ketterer, N. et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998, 92: 1927-32.
26. Hainsworth, J., Litchy, S., Barton, J. et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003, 21: 1746-51.
27. Paydas, S., Yavuz, S., Disel, U., Sahin, B., Ergin, M. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk Lymphoma 2003, 44: 2165-6.
28. Igarashi, T., Kobayashi, Y., Ogura, M. et al. IDEC-C2B8 Study Group in Japan. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study. Ann Oncol 2002, 13: 928-43.
29. Conconi, A., Martinelli, G., Thieblemont, C. et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003, 102: 2741-5.
30. Raderer, M., Jager, G., Brugger, S. et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003, 65: 306-10.
31. Dimopoulos, M., Zervas, C., Zomas, A., et al. Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression. Leuk Lymphoma 2002, 45: 2057-61.
32. McHeyzer-Williams, M., Ahmed, R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999, 11: 172-9.
33. Stasi, R., Pagano, A., Stipa, E., Amadori, S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001, 98: 952-7.
34. Edwards, J., Cambridge, G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001, 40: 205-11.
35. Cambridge, G., Leandro, M., Edwards, J. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003, 48: 2146-54.
36. George, J., el-Harake, M., Raskob, G. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994, 331: 1207-11.
37. Portielje, J., Westendorp, R., Nelemans, H., Brand, A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001, 97: 2549-54.
38. Zaja, F., Vianelli, N., Sperotto, A. et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003, 88: 538-46.
39. Braendstrup, P., Bjerrum, O., Nielsen, O. et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005, 78: 275-80.
40. Kojouri, K., George, J. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura. Int J Hematol 2005, 81: 119-25.
41. Zaja, F., Iacona, I., Masolini, P. et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002, 87: 189-95.
42. Ramanathan, S., Koutts, J., Hertzberg, M. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol 2005, 78: 123-6.
43. Robak, T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004, 72: 79-88.
44. Mantadakis, E., Danilatou, V., Stiakaki, E., Kalmanti, M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol 2004, 77: 303-10.
45. Doan, T., Massarotti, E. Rheumatoid arthritis: An overview of new and emerging therapies. J Clin Pharmacol 2005, 45: 751-62.
46. Silverman, G., Carson, D. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003, 5: S1-S6.
47. Roosnek, E., Lanzavecchia, A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991, 173: 487-9.
48. van Zeben, D., Hazes, J., Zwinderman, A., Cats, A., van der Voort, E., Breedveld, F. Clinical significance of rheumatoid factors in early rheumatoid arthritis: Results of a follow-up study. Ann Rheum Dis 1992, 51: 1029-35.
49. Forslind, K., Ahlmen, M., Eberhardt, K., Hafstrom, I., Svensson, B., BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004, 63: 1090-5.
50. Gardner, D. Rheumatoid arthritis: Cell and tissue pathology. In: Pathological Basis of Connective Tissue Diseases. Edward Arnold: London 1992, 444-526.
51. Edwards, J., Cambridge, G., Abrahams, V. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999, 97: 188-96.
52. Takemura, S., Klimiuk, P., Braun, A., Goronzy, J., Weyand, C. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001, 167: 4710-8.
53. Kneitz, C., Wilhelm, M., Tony, H. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 2004, 33: 82-6.
54. De Vita, S., Zaja, F., Sacco, S., De Candia, A., Fanin, R., Ferraccioli, G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis Rheum 2002, 46: 2029-33.
55. Kramm, H., Hansen, K., Gowing, E., Bridges, A. Successful therapy of rheumatoid arthritis with rituximab. Renewed interest in the role of B cells in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2004, 10: 28-32.
56. Stahl, H., Szczepanski, L., Szechinski, J. et al. Rituximab in RA: Efficacy and safety from a randomised controlled trial. The Annual European Congress of Rheumatology: Recent Advances in the Treatment of Rhematoic Diseases, Lisbon 2003, Abst. OP004.
57. Edwards, J., Szczepanski, L., Szechinski, J. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350: 2572-81.
58. Keystone, E., Burmester, G., Furie, R. et al. Improved quality of life with rituximab plus methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TNF-α therapies. ACR/ ARHP Annual Scientific Meeting, San Diego 2005, Abst. 287.
59. Breedveld, F., Agarwal, S., Yin, M. et al. Relationship between clinical response, rituximab pharmacokinetics, and peripheral B cell levels in rheumatoid arthritis. Arthritis Rheum 2005, 52: S138.
60. Fleischmann, R., Pavelka, K., Baldassare, A. et al. Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. 264.
61. Emery, P., Fleischmann, R., Pavelka, K. et al. Safety and tolerability of rituximab retreatment in patients with active rheumatoid arthritis. Arthritis Rheum 2005, 52: S351.
62. Fleischmann, R., Racewicz, A., Schechtman, J. et al. Rituximab efficacy in rheumatoid arthritis is independent of coadministration of glucocorticoids: Results from the Dose-Ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Study. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. 263.
63. van Vollenhoven, R., Schechtman, J., Szczepanski, L. et al. Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: Results from the Dose-Ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Study. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. 1922.
64. Cohen, S., Greenwald, M., Dougados, M. et al. Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF therapies (REFLEX Study). ARC/ARHP Annual Scientific Meeting, San Diego 2005, Abst. 1830.
65. Lipsky, P. Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Immunology 2001, 2: 764-6.
66. Anolik, J., Barnard, J., Cappione, A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50: 3580-90.
67. Looney, R., Anolik, J., Campbell, D. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50: 2580-9.
68. Abu-Shakra, M., Urowitz, M., Gladman, D., Gough, J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995, 22: 1259-64.
69. Leandro, M., Edwards, J., Cambridge, G., Ehrenstein, M., Isenberg, D. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46: 2673-7.
70. Albert, D., Kahn, S., Stansberry, J., Tsai, D., Eisenberg, R. A phase 1 trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus. ACR/ARHP Annual Scientific Meeting, San Antonio 2004, Abst. 1125.
71. Anolik, J., Campbell, D., Felgar, R. et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003, 48: 455-9.
72. Leandro, M., Edwards, J., Ehrenstein, M., Cambridge, G., Isenberg, D. B lymphocyte depletion in the treatment of systemic lupus erythematosus. ACR/ARHP Annual Scientific Meeting, San Antonio 2004, Abst. 1126.
73. Tahir, H., Rohrer, J., Bhatia, A., Wegener, W., Isenberg, D. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology 2005, 44: 561-2.
74. Ng, K., Leandro, M., Edwards, J., Ehrenstein, M., Cambridge, G., Isenberg, D. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. 449.
75. Sfikakis, P., Boletis, J., Lionaki, S. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum 2005, 52: 501-13.
76. Mok, C., Wong, R., Lai, K. Treatment of severe proliferative lupus nephritis: The current state. Ann Rheum Dis 2003, 62: 799-804.
77. Marks, S., Patey, S., Brogan, P. et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005, 52: 3168-74.
78. Edelbauer, M., Jungraithmayr, T., Zimmerhackl, L. Rituximab in childhood systemic lupus erythematosus refractory to conventional immuno-suppression: Case report. Pediatr Nephrol 2005, 20: 811-3.
79. Cruz, M., Spencer, C., Wagner-Weiner, L., Onel, K. Retrospective review of rituximab therapy in pediatric systemic lupus erythematosus refractory to immunosuppressive therapy. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. F78.
80. Levy, D., Adams, B., Kahn, P., Imundo, L. Rituximab in treatment-resistant childhood-onset systemic lupus erythematosus. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. 1406.
81. Tanaka, Y., Tokunaga, M., Kawabata, D. et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. 431.
82. Levine, T. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 2005, 52: 601-7.
83. Sultan, S., Isenberg, D., Cambridge, G., Edwards, J. Clinical outcome in 7 patients with idiopathic inflammatory myositis treated with rituximab. ACR/ARHP Annual Scientific Conference San Diego 2005, Abst. 791.
84. Chung, L., Genovese, M., Fiorentino, D. Rituximab in the treatment of patients with dermatomyositis: 12 week interim analysis of a pilot trial. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. F61.
85. Endo, L., Theos, A., Prescott Atkinson, T. Use of rituximab in refractory juvenile dermatomyositis. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. 710.
86. Pestronk, A., Florence, J., Miller, T., Choksi, R., Al-Lozi, M., Levine, T. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003, 74: 485-9.
87. Specks, U., Fervenza, F., McDonald, T., Hogan, M. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44: 2836-40.
88. Eriksson, P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005, 257: 540-8.
89. Omdal, R., Wildhagen, K., Hansen, T., Gunnarsson, R., Kristoffersen, G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response. Scand J Rheumatol 2005, 34: 229-32.
90. Pijpe, J., van Imhoff, G., Spijkervet, F. et al. Rituximab treatment in patients with primary Sjogren's syndrome: An open-label phase II study. Arthritis Rheum 2005, 52: 2740-50.
91. Seror, R., Sordet, C., Gottenberg, J.E. et al. Good tolerance and efficacy of rituximab on systemic features in 12 patients with primary Sjogren's syndrome. ACR/ARHP Annual Scientific Meeting, San Diego 2005, Abst. 970.
92. Zaja, F., De Vita, S., Mazzaro, C. et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101: 3827-34.
93. Arzoo, K., Sadeghi, S., Liebman, H. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002, 61: 922-4.
94. Zaja, F., Russo, D., Fuga, G., Perella, G., Baccarani, M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000, 55: 1062-3.
95. Wylam, M., Anderson, P., Kuntz, N., Rodriguez, V. Successful treatment of refractory myasthenia gravis using rituximab: A pediatric case report. J Pediatr 2004, 143: 674-7.
96. Gajra, A., Vajpayee, N., Grethlein, S. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol 2004, 77: 196-9.
97. Arin, M., Hunzelmann, N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus - an update. Eur J Dermatol 2005, 15: 224-30.
98. Shaw, T., Quan, J. B cell therapy for rheumatoid arthritis: The rituximab (anti-CD20) experience. Ann Rheum Dis 2003, 62: ii55-9.
99. Johnson, P., Glennie, M. Rituximab: Mechanisms and applications. Br J Cancer 2001, 85: 1619-23.
100. Genetech Inc. Rituxan [package insert]. San Francisco, Genetech Inc., 2004.